Which has better earnings & valuation, IPHA or SPRY?

Innate Pharma has higher earnings, but lower revenue than ARS Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innate Pharma $2.79M 59.99 -$55.64M N/A N/A ARS Pharmaceuticals $98.99M 5.96 -$171.30M -$2.01 N/A

Does the media favor IPHA or SPRY?

In the previous week, ARS Pharmaceuticals had 4 more articles in the media than Innate Pharma. MarketBeat recorded 7 mentions for ARS Pharmaceuticals and 3 mentions for Innate Pharma. ARS Pharmaceuticals' average media sentiment score of 0.54 beat Innate Pharma's score of 0.39 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innate Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ARS Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has preferable valuation & earnings, IPHA or ALLO?

Innate Pharma has higher revenue and earnings than Allogene Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innate Pharma $2.79M 59.99 -$55.64M N/A N/A Allogene Therapeutics N/A N/A -$190.89M -$0.77 N/A

Is IPHA or ALLO more profitable?

Innate Pharma's return on equity of 0.00% beat Allogene Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Innate Pharma N/A N/A N/A Allogene Therapeutics N/A -56.45% -40.36%

Does the media prefer IPHA or ALLO?

In the previous week, Innate Pharma had 1 more articles in the media than Allogene Therapeutics. MarketBeat recorded 3 mentions for Innate Pharma and 2 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 1.56 beat Innate Pharma's score of 0.39 indicating that Allogene Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innate Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Allogene Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has higher earnings and valuation, CRMD or IPHA?

CorMedix has higher revenue and earnings than Innate Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CorMedix $400.05M 1.54 $163.05M $2.13 3.69 Innate Pharma $2.79M 59.99 -$55.64M N/A N/A

Does the media refer more to CRMD or IPHA?

In the previous week, CorMedix and CorMedix both had 3 articles in the media. CorMedix's average media sentiment score of 1.07 beat Innate Pharma's score of 0.39 indicating that CorMedix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CorMedix 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Innate Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, IPHA or TECX?

Innate Pharma has higher revenue and earnings than Tectonic Therapeutic. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innate Pharma $2.79M 59.99 -$55.64M N/A N/A Tectonic Therapeutic N/A N/A -$74.15M -$4.46 N/A

Is IPHA or TECX more profitable?

Innate Pharma's return on equity of 0.00% beat Tectonic Therapeutic's return on equity. Company Net Margins Return on Equity Return on Assets Innate Pharma N/A N/A N/A Tectonic Therapeutic N/A -32.33% -30.92%

Does the media prefer IPHA or TECX?

In the previous week, Innate Pharma and Innate Pharma both had 3 articles in the media. Innate Pharma's average media sentiment score of 0.39 beat Tectonic Therapeutic's score of 0.19 indicating that Innate Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innate Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Tectonic Therapeutic 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, IPHA or CTMX?

CytomX Therapeutics has higher revenue and earnings than Innate Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innate Pharma $2.79M 59.99 -$55.64M N/A N/A CytomX Therapeutics $76.20M 7.24 -$17.37M -$0.41 N/A

Does the media prefer IPHA or CTMX?

In the previous week, CytomX Therapeutics had 1 more articles in the media than Innate Pharma. MarketBeat recorded 4 mentions for CytomX Therapeutics and 3 mentions for Innate Pharma. CytomX Therapeutics' average media sentiment score of 1.23 beat Innate Pharma's score of 0.39 indicating that CytomX Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innate Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral CytomX Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Innate Pharma (IPHA) Competitors

$1.78 +0.02 (+1.14%)

Closing price 07/24/2026 03:59 PM Eastern

Extended Trading

$1.78 +0.00 (+0.28%)

As of 07/24/2026 06:46 PM Eastern

Compare

IPHA vs. SPRY, ALLO, CRMD, TECX, and CTMX

Should you buy Innate Pharma stock or one of its competitors? MarketBeat compares Innate Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Innate Pharma include ARS Pharmaceuticals (SPRY), Allogene Therapeutics (ALLO), CorMedix (CRMD), Tectonic Therapeutic (TECX), and CytomX Therapeutics (CTMX). These companies are all part of the "pharmaceutical products" industry.

How does Innate Pharma compare to ARS Pharmaceuticals?

Innate Pharma (NASDAQ:IPHA) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

In the previous week, ARS Pharmaceuticals had 4 more articles in the media than Innate Pharma. MarketBeat recorded 7 mentions for ARS Pharmaceuticals and 3 mentions for Innate Pharma. ARS Pharmaceuticals' average media sentiment score of 0.54 beat Innate Pharma's score of 0.39 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innate Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
ARS Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Innate Pharma has higher earnings, but lower revenue than ARS Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$2.79M	59.99	-$55.64M	N/A	N/A
ARS Pharmaceuticals	$98.99M	5.96	-$171.30M	-$2.01	N/A

Innate Pharma has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market.

Innate Pharma has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. Innate Pharma's return on equity of 0.00% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%

Innate Pharma presently has a consensus target price of $5.00, suggesting a potential upside of 180.90%. ARS Pharmaceuticals has a consensus target price of $28.20, suggesting a potential upside of 374.75%. Given ARS Pharmaceuticals' higher probable upside, analysts plainly believe ARS Pharmaceuticals is more favorable than Innate Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

0.2% of Innate Pharma shares are held by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 31.9% of Innate Pharma shares are held by company insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

ARS Pharmaceuticals beats Innate Pharma on 8 of the 14 factors compared between the two stocks.

How does Innate Pharma compare to Allogene Therapeutics?

Innate Pharma (NASDAQ:IPHA) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

Innate Pharma presently has a consensus price target of $5.00, indicating a potential upside of 180.90%. Allogene Therapeutics has a consensus price target of $8.52, indicating a potential upside of 389.78%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Allogene Therapeutics is more favorable than Innate Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

Innate Pharma has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market.

Innate Pharma has higher revenue and earnings than Allogene Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$2.79M	59.99	-$55.64M	N/A	N/A
Allogene Therapeutics	N/A	N/A	-$190.89M	-$0.77	N/A

Innate Pharma's return on equity of 0.00% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
Allogene Therapeutics	N/A	-56.45%	-40.36%

In the previous week, Innate Pharma had 1 more articles in the media than Allogene Therapeutics. MarketBeat recorded 3 mentions for Innate Pharma and 2 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 1.56 beat Innate Pharma's score of 0.39 indicating that Allogene Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innate Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Allogene Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

0.2% of Innate Pharma shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 31.9% of Innate Pharma shares are owned by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Innate Pharma and Allogene Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Innate Pharma compare to CorMedix?

CorMedix (NASDAQ:CRMD) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

CorMedix has a net margin of 45.25% compared to Innate Pharma's net margin of 0.00%. CorMedix's return on equity of 45.57% beat Innate Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	45.25%	45.57%	24.76%
Innate Pharma	N/A	N/A	N/A

In the previous week, CorMedix and CorMedix both had 3 articles in the media. CorMedix's average media sentiment score of 1.07 beat Innate Pharma's score of 0.39 indicating that CorMedix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CorMedix	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Innate Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

CorMedix currently has a consensus price target of $14.86, indicating a potential upside of 88.78%. Innate Pharma has a consensus price target of $5.00, indicating a potential upside of 180.90%. Given Innate Pharma's higher probable upside, analysts clearly believe Innate Pharma is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

CorMedix has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market. Comparatively, Innate Pharma has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market.

CorMedix has higher revenue and earnings than Innate Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$400.05M	1.54	$163.05M	$2.13	3.69
Innate Pharma	$2.79M	59.99	-$55.64M	N/A	N/A

34.2% of CorMedix shares are owned by institutional investors. Comparatively, 0.2% of Innate Pharma shares are owned by institutional investors. 3.5% of CorMedix shares are owned by company insiders. Comparatively, 31.9% of Innate Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

CorMedix beats Innate Pharma on 10 of the 14 factors compared between the two stocks.

How does Innate Pharma compare to Tectonic Therapeutic?

Innate Pharma (NASDAQ:IPHA) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

0.2% of Innate Pharma shares are held by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are held by institutional investors. 31.9% of Innate Pharma shares are held by insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Innate Pharma and Innate Pharma both had 3 articles in the media. Innate Pharma's average media sentiment score of 0.39 beat Tectonic Therapeutic's score of 0.19 indicating that Innate Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innate Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tectonic Therapeutic	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Innate Pharma presently has a consensus price target of $5.00, suggesting a potential upside of 180.90%. Tectonic Therapeutic has a consensus price target of $79.40, suggesting a potential upside of 161.44%. Given Innate Pharma's higher probable upside, analysts clearly believe Innate Pharma is more favorable than Tectonic Therapeutic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Tectonic Therapeutic	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.75

Innate Pharma has higher revenue and earnings than Tectonic Therapeutic.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$2.79M	59.99	-$55.64M	N/A	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.46	N/A

Innate Pharma has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.21, suggesting that its share price is 221% more volatile than the broader market.

Innate Pharma's return on equity of 0.00% beat Tectonic Therapeutic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
Tectonic Therapeutic	N/A	-32.33%	-30.92%

Summary

Innate Pharma and Tectonic Therapeutic tied by winning 6 of the 12 factors compared between the two stocks.

How does Innate Pharma compare to CytomX Therapeutics?

Innate Pharma (NASDAQ:IPHA) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

0.2% of Innate Pharma shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 31.9% of Innate Pharma shares are owned by company insiders. Comparatively, 3.8% of CytomX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Innate Pharma has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -166.40%. Innate Pharma's return on equity of 0.00% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
CytomX Therapeutics	-166.40%	-36.61%	-28.02%

CytomX Therapeutics has higher revenue and earnings than Innate Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$2.79M	59.99	-$55.64M	N/A	N/A
CytomX Therapeutics	$76.20M	7.24	-$17.37M	-$0.41	N/A

In the previous week, CytomX Therapeutics had 1 more articles in the media than Innate Pharma. MarketBeat recorded 4 mentions for CytomX Therapeutics and 3 mentions for Innate Pharma. CytomX Therapeutics' average media sentiment score of 1.23 beat Innate Pharma's score of 0.39 indicating that CytomX Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innate Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
CytomX Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Innate Pharma presently has a consensus target price of $5.00, indicating a potential upside of 180.90%. CytomX Therapeutics has a consensus target price of $12.10, indicating a potential upside of 273.46%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CytomX Therapeutics is more favorable than Innate Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00

Innate Pharma has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.08, indicating that its stock price is 108% more volatile than the broader market.

Summary

CytomX Therapeutics beats Innate Pharma on 10 of the 15 factors compared between the two stocks.

Get Innate Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IPHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IPHA vs. The Competition

Export

Metric	Innate Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$165.30M	$3.67B	$6.87B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	N/A	21.29	27.11	23.64
Price / Sales	59.99	160.31	512.89	89.27
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	-6.85	7.88	10.28	6.07
Net Income	-$55.64M	$23.86M	$3.60B	$331.99M
7 Day Performance	1.71%	-3.82%	-1.27%	-0.63%
1 Month Performance	-0.56%	-2.61%	-0.37%	-2.00%
1 Year Performance	-12.75%	32.79%	18.30%	13.62%

Innate Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IPHA Innate Pharma	2.5555 of 5 stars	$1.78 +1.1%	$5.00 +180.9%	-12.5%	$165.30M	$2.79M	N/A	220	News Coverage Gap Up
SPRY ARS Pharmaceuticals	2.2911 of 5 stars	$6.36 -1.2%	$28.20 +343.4%	-66.9%	$639.51M	$84.28M	N/A	90	High Trading Volume
ALLO Allogene Therapeutics	2.6182 of 5 stars	$1.85 +4.5%	$8.52 +360.7%	+15.2%	$610.92M	N/A	N/A	310
CRMD CorMedix	2.9877 of 5 stars	$8.19 +5.3%	$14.86 +81.4%	-31.6%	$610.36M	$311.71M	3.85	30	Positive News
TECX Tectonic Therapeutic	3.2959 of 5 stars	$32.80 +2.3%	$79.40 +142.1%	+36.3%	$605.14M	N/A	N/A	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IPHA) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Innate Pharma (IPHA) Competitors

IPHA vs. SPRY, ALLO, CRMD, TECX, and CTMX

How does Innate Pharma compare to ARS Pharmaceuticals?

Summary

How does Innate Pharma compare to Allogene Therapeutics?

Summary

How does Innate Pharma compare to CorMedix?

Summary

How does Innate Pharma compare to Tectonic Therapeutic?

Summary

How does Innate Pharma compare to CytomX Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHA vs. The Competition

Innate Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Innate Pharma (IPHA) Competitors

IPHA vs. SPRY, ALLO, CRMD, TECX, and CTMX

How does Innate Pharma compare to ARS Pharmaceuticals?

Does the media favor IPHA or SPRY?

Which has better earnings & valuation, IPHA or SPRY?

Which has more risk & volatility, IPHA or SPRY?

Is IPHA or SPRY more profitable?

Do analysts rate IPHA or SPRY?

Do institutionals and insiders believe in IPHA or SPRY?

Summary

How does Innate Pharma compare to Allogene Therapeutics?

Do analysts prefer IPHA or ALLO?

Which has more risk & volatility, IPHA or ALLO?

Which has preferable valuation & earnings, IPHA or ALLO?

Is IPHA or ALLO more profitable?

Does the media prefer IPHA or ALLO?

Do institutionals and insiders believe in IPHA or ALLO?

Summary

How does Innate Pharma compare to CorMedix?

Is CRMD or IPHA more profitable?

Does the media refer more to CRMD or IPHA?

Do analysts rate CRMD or IPHA?

Which has more volatility & risk, CRMD or IPHA?

Which has higher earnings and valuation, CRMD or IPHA?

Do institutionals & insiders have more ownership in CRMD or IPHA?

Summary

How does Innate Pharma compare to Tectonic Therapeutic?

Do insiders and institutionals hold more shares of IPHA or TECX?

Does the media prefer IPHA or TECX?

Do analysts prefer IPHA or TECX?

Which has better earnings and valuation, IPHA or TECX?

Which has more risk and volatility, IPHA or TECX?

Is IPHA or TECX more profitable?

Summary

How does Innate Pharma compare to CytomX Therapeutics?

Do institutionals & insiders have more ownership in IPHA or CTMX?

Is IPHA or CTMX more profitable?

Which has higher valuation & earnings, IPHA or CTMX?

Does the media prefer IPHA or CTMX?

Do analysts prefer IPHA or CTMX?

Which has more risk and volatility, IPHA or CTMX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHA vs. The Competition

Innate Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools